CD8+ CD28- regulatory T cells after induction therapy predict progression-free survival in myeloma patients: results from the GMMG-HD6 multicenter phase III study

被引：0

作者：

Kriegsmann, Katharina ^{[1
,2
]}

Ton, Gigi Nu Hoang Quy ^{[1
]}

Awwad, Mohamed H. S. ^{[1
]}

Benner, Axel ^{[3
]}

Bertsch, Uta ^{[1
,4
]}

Besemer, Britta ^{[5
]}

Haenel, Mathias ^{[6
]}

Fenk, Roland ^{[7
]}

Munder, Markus ^{[8
]}

Duerig, Jan ^{[9
]}

Blau, Igor W. ^{[10
]}

Huhn, Stefanie ^{[1
]}

Hose, Dirk ^{[1
]}

Jauch, Anna ^{[11
]}

Mann, Christoph ^{[12
]}

Weinhold, Niels ^{[1
]}

Scheid, Christof ^{[13
]}

Schroers, Roland ^{[14
]}

von Metzler, Ivana ^{[15
]}

Schieferdecker, Aneta ^{[16
]}

Thomalla, Joerg ^{[17
]}

Reimer, Peter ^{[18
]}

Mahlberg, Rolf ^{[19
]}

Graeven, Ullrich ^{[20
]}

Kremers, Stephan ^{[21
]}

Martens, Uwe M. ^{[22
]}

Kunz, Christian ^{[23
]}

Hensel, Manfred ^{[24
]}

Seidel-Glaetzer, Andrea ^{[25
]}

Weisel, Katja C. ^{[16
]}

Salwender, Hans J. ^{[26
]}

Mueller-Tidow, Carsten ^{[1
,4
,27
,28
]}

Raab, Marc S. ^{[1
]}

Goldschmidt, Hartmut ^{[1
,4
]}

Mai, Elias K. ^{[1
]}

Hundemer, Michael ^{[1
]}

机构：

[1] Heidelberg Univ Hosp, Dept Internal Med 5, Heidelberg, Germany

[2] Laborarztpraxis Rhein Main MVZ GbR, Frankfurt, Germany

[3] German Canc Res Ctr DKFZ Heidelberg, Div Biostat, Heidelberg, Germany

[4] Natl Ctr Tumor Dis Heidelberg, Heidelberg, Germany

[5] Univ Hosp Tubingen, Dept Internal Med 2, Tubingen, Germany

[6] Klinikum Chemnitz, Dept Internal Med 3, Chemnitz, Germany

[7] Univ Hosp Dusseldorf, Dept Hematol Oncol & Clin Immunol, Dusseldorf, Germany

[8] Univ Hosp Mainz, Dept Internal Med 3, Mainz, Germany

[9] Univ Hosp Essen, Dept Hematol & Stem Cell Transplantat, Essen, Germany

[10] Charite Univ Med Berlin, Med Clin, Berlin, Germany

[11] Heidelberg Univ, Inst Human Genet, Heidelberg, Germany

[12] Phillips Univ Marburg, Dept Hematol Oncol & Immunol, Marburg, Germany

[13] Univ Hosp Cologne, Dept Internal Med 1, Cologne, Germany

[14] Ruhr Univ Bochum, Dept Hematol Oncol, Bochum, Germany

[15] Univ Hosp Frankfurt aM, Dept Internal Med 2, Frankfurt, Germany

[16] Univ Med Ctr Hamburg Eppendorf, Dept Oncol Hematol & Bone Marrow Transplantat, Sect Pneumol, Hamburg, Germany

[17] Hematol Oncol Ctr, Koblenz, Germany

[18] Evang Krankenhaus Essen Werden, Evang Kliniken Essen Mitte, Essen, Germany

[19] Hosp Mutterhaus Borromaerinnen, Internal Med 1, Trier, Germany

[20] Kliniken Maria Hilf GmbH, Dept Hematol Oncol & Gastroenterol, Monchengladbach, Germany

[21] Hematol Oncol Ctr, Lebach, Germany

[22] SLK Clin Heilbronn, Hematol Oncol Palliat Care, Heilbronn, Germany

[23] Westpfalz Klinikum, Hematol & Oncol, Kaiserslautern, Germany

[24] Mannheimer Onkol Praxis, Mannheim, Germany

[25] Coordinat Ctr Clin Trials KKS Heidelberg, Heidelberg, Germany

[26] Asklepios Hosp Hamburg Altona & St Georg, Asklepios Tumorzentrum Hamburg, Hamburg, Germany

[27] Heidelberg Univ, Mol Med Partnership Unit MMPU, Heidelberg, Germany

[28] European Mol Biol Lab EMBL, Heidelberg, Germany

来源：

LEUKEMIA | 2024年 / 38卷 / 07期

关键词：

ELOTUZUMAB PLUS LENALIDOMIDE/DEXAMETHASONE; FOLLOW-UP; ELOQUENT-2;

D O I：

10.1038/s41375-024-02290-y

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1621 / 1625

页数：5

共 5 条

[1] Long-Term Follow-up Analysis of Progression-Free and Overall Survival in Newly Diagnosed Multiple Myeloma Patients from the GMMG Myeloma Registry Following the Randomized Phase III GMMG-HD6 Trial
Keller, Anne-Valerie
Hajiyianni, Marina
Kurre, Eileen
Mai, Elias Karl
Bertsch, Uta
Benner, Axel
Luntz, Steffen
Raab, Marc-Steffen
Besemer, Britta
Michel, Christian Sebastian
Schroers, Roland
Fenk, Roland
Salwender, Hans
Blau, Igor Wolfgang
Haenel, Mathias
Mann, Christoph
Goldschmidt, Hartmut
BLOOD, 2024, 144 : 5140 - 5142
[2] Trajectories of CD4+/CD8+ T-Cells Ratio 96 Weeks after Switching to Dolutegravir-Based Two-Drug Regimens: Results from a Multicenter Prospective Cohort Study
Taramasso, Lucia
Falletta, Antonio
Ricci, Elena
Orofino, Giancarlo
Squillace, Nicola
Menzaghi, Barbara
De Socio, Giuseppe Vittorio
Molteni, Chiara
Pellicano, Giovanni Francesco
Gulminetti, Roberto
Madeddu, Giordano
Sarchi, Eleonora
Vichi, Francesca
Celesia, Benedetto Maurizio
Bonfanti, Paolo
Di Biagio, Antonio
VIRUSES-BASEL, 2022, 14 (11):
[3] Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: Results of a multicenter randomized controlled trial
Stewart, AK
Vescio, R
Schiller, G
Ballester, O
Noga, S
Rugo, H
Freytes, C
Stadtmauer, E
Tarantolo, S
Sahebi, F
Stiff, P
Meharchard, J
Schlossman, R
Brown, R
Tully, H
Benyunes, M
Jacobs, C
Berenson, R
White, M
DiPersio, J
Anderson, KC
Berenson, J
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (17) : 3771 - 3779
[4] Bortezomib-Based Induction and Maintenance Overcomes the Negative Prognostic Impact of Renal Impairment and del17p in Transplant-Eligible Myeloma Patients: Long Term Results from the Phase III HOVON-65/GMMG-HD4 Study after Median 137 Months Follow up
Scheid, Christof
Lokhorst, Henk
Blau, Igor W.
Van der Holt, Bronno
Bertsch, Uta
Zweegman, Sonja
Weisel, Katja
Vellenga, Edo
Kersten, Marie Jose
Croockewit, Sandra
Mai, Elias K.
Raymakers, Reinier
Hose, Dirk
Jauch, Anna
Hillengass, Jens
Stevens-Kroef, Marian
Raab, Marc S.
Neben, Kai
Stilgenbauer, Stephan
Broyl, Annemiek
Lindemann, Hans-Walter
Bos, Gerard
Brossart, Peter
Kooij, Marinus van Marwijk
Ypma, Paula F.
Duehrsen, Ulrich
Schaafsma, Ron
Hielscher, Thomas
Salwender, Hans
Goldschmidt, Hartmut
Sonneveld, Pieter
BLOOD, 2019, 134
[5] Prognostic Importance of Measurable Residual Disease (MRD) Kinetics and Progression-Free Survival (PFS) Benefit in MRD plus Patients (Pts) with Ixazomib Vs Placebo As Post-Induction Maintenance Therapy: Results from the Multicenter, Double-Blind, Phase 3 TOURMALINE-MM4 Trial in Non-Transplant Newly Diagnosed Multiple Myeloma (NDMM) Pts
Paiva, Bruno
Manrique, Irene
Giuliani, Nicola
Cavo, Michele
Rojas, Christine
Fu, Weijun
Mateos, Maria-Victoria
Dimopoulos, Meletios A.
Vorog, Alexander
Li, Cong
Wang, Bingxia
Labotka, Richard J.
Dash, Ajeeta B.
BLOOD, 2020, 136

← 1 →